Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
04
03
2022
accepted:
10
05
2022
pubmed:
27
5
2022
medline:
22
11
2022
entrez:
26
5
2022
Statut:
epublish
Résumé
Allergic asthma is associated with increased risk of respiratory tract infections and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal or by perennial allergy. To investigate perennial allergy compared with seasonal allergy as a risk factor for lower respiratory tract infections and exacerbations in asthma and whether this risk can be reduced by allergen immunotherapy (AIT). This is a prospective register-based nationwide study of 18-44-year-olds treated with AIT during 1995-2014. Based on the type of AIT and use of anti-asthmatic drugs, patients were subdivided into two groups: perennial allergic asthma (PAA) We identified 2688 patients with asthma treated with AIT, of whom 1249 had PAA and 1439 had SAA. At baseline, patients with SAA had more exacerbations (23.8% AIT effectively reduced the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma. Perennial allergy is seemingly not a stronger risk factor for respiratory infections and exacerbations than seasonal allergy.
Sections du résumé
BACKGROUND
Allergic asthma is associated with increased risk of respiratory tract infections and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal or by perennial allergy.
AIM
To investigate perennial allergy compared with seasonal allergy as a risk factor for lower respiratory tract infections and exacerbations in asthma and whether this risk can be reduced by allergen immunotherapy (AIT).
METHODOLOGY
This is a prospective register-based nationwide study of 18-44-year-olds treated with AIT during 1995-2014. Based on the type of AIT and use of anti-asthmatic drugs, patients were subdivided into two groups: perennial allergic asthma (PAA)
RESULTS
We identified 2688 patients with asthma treated with AIT, of whom 1249 had PAA and 1439 had SAA. At baseline, patients with SAA had more exacerbations (23.8%
CONCLUSION
AIT effectively reduced the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma. Perennial allergy is seemingly not a stronger risk factor for respiratory infections and exacerbations than seasonal allergy.
Identifiants
pubmed: 35618279
pii: 13993003.00446-2022
doi: 10.1183/13993003.00446-2022
pii:
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Déclaration de conflit d'intérêts
Conflict of interest: C. Woehlk has received speaker fees from ALK Abelló Nordic A/s. M.B. Søndergaard reports speaker fees from GlaxoSmithKline. A. Von Bülow has received speaker fees from AstraZeneca, GlaxoSmithKline and Novartis, and has attended advisory boards for Novartis and AstraZeneca. C. Porsbjerg reports grants or contracts from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s paid to institution; consulting fees from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s; speaker fees from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s; advisory board honoraria from AstraZeneca, Novartis, TEVA, Sanofi, and ALK Abelló A/s. M. Ghanizada and S. Hansen report no conflicts of interest.